Moderna dealt blows in ongoing patent dispute with Arbutus
Source: SeekingAlpha
2026-02-18 09:42:45 ET
More on Moderna
- Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
- Moderna, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case
- Moderna gains as FDA backtracks and accepts flu shot for review
- Changes to U.S. vaccine policy under RFK Jr. challenged in court
Read the full article on Seeking Alpha
For further details see:
Moderna dealt blows in ongoing patent dispute with Arbutus
Arbutus Biopharma Corporation
NASDAQ: ABUS
ABUS Trading
3.34% G/L:
$4.635 Last:
925,635 Volume:
$4.43 Open:
ABUS Latest News
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
November 13, 2025 07:30:00 am
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 07, 2025 08:00:00 am
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
ABUS Stock Data
$811,607,352
153,282,242
0.14%
53
N/A
Biotechnology & Life Sciences
Healthcare
US
Warminster
